Eticovo FDA Approval History
Last updated by Judith Stewart, BPharm on Feb 16, 2021.
FDA Approved: Yes (First approved April 25, 2019)
Brand name: Eticovo
Generic name: etanercept-ykro
Dosage form: Injection
Company: Samsung Bioepis Co., Ltd.
Eticovo (etanercept-ykro) is a tumor necrosis factor (TNF) blocker biosimilar to Enbrel indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
- The FDA approval of Eticovo was based on the results of a Phase III clinical study confirming that Eticovo demonstrated comparable safety and efficacy to the reference product Enbrel.
- Eticovo is administered by subcutaneous injection.
- Eticovo comes with a Boxed Warning alerting health care professionals and patients of the increased risk of serious infections and malignancies.
- The most common reported side effects of Eticovo include infections and injection site reactions.
Development timeline for Eticovo
| Date | Article |
|---|---|
| Apr 27, 2019 | Approval FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.